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Abstract: Statins are reported to reduce the risk of cancer, but the results of various published studies
have been contradictory. We carried out an umbrella review to provide an overview and understand
the strength of evidence, extent of potential biases, and validity of claimed associations between the
use of statins and cancer incidence. We comprehensively re-analyzed the data of meta-analyses of
randomized controlled trials (RCTs) and observational studies on associations between statin use and
cancer incidence. We also assessed the strength of evidence of the re-analyzed outcomes, which were
determined from the criteria including statistical significance of the p-value of random-effects, as well
as fixed-effects meta-analyses, small study effects, between-study heterogeneity, and a 95% prediction
interval. Using a conventional method to assess the significance of meta-analysis (p-value < 0.05),
statins had a statistically significant effect on reducing cancer incidence in 10 of 18 types of cancer.
When we graded the level of evidence, no cancer type showed convincing evidence, and four cancers
(esophageal cancer, hematological cancer, leukemia, and liver cancer) showed suggestive evidence of
a preventive effect. There was weak evidence of an association with six cancers, and no significance
for the remaining eight cancers. None of the meta-analyses of RCTs on the association of statin and
cancer incidence showed a statistical significance. Although there was a preventive effect of statin on
cancer incidence in 10 of the 18 cancer types, the evidence supporting the use of statins to reduce
cancer incidence was low. Therefore, the associations between statin use and cancer incidence should
be carefully considered by clinicians.
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1. Introduction
Cancer places one of the biggest burdens on health care system in both highly developed and less
developed countries, and its incidence and mortality have been increasing for decades mainly due to
longer life expectancy [1]. Based on cancer statistics, 14.1 million new cancers occurred in 2012, while
8.2 million people died of cancer [2]. Despite the efforts of industry and physicians, overall survival
and progression-free survival is still unsatisfactory for most cancer types.
Statins, competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, have been
used for lowering cholesterol levels [3]. Because of this effect of statin, statins have proven to be effective
in reducing the risk of vascular diseases, such as coronary artery disease and stroke [4,5]. Besides their
lipid-lowering effects, statins also exhibit anti-inflammatory, immunomodulatory and antithrombotic
effects [6–8]. It has been proposed that statins also have anti-tumor effects. The mechanism of anti-tumor
effect is poorly understood, but some in vitro studies indicate that statins suppress proliferation of tumor
cells and angiogenesis [9,10]. Furthermore, epidemiologic studies, clinical trials and meta-analyses
also support this benefit in different types of cancer, yet there is a lack of studies, and conflicting results
on the relationship between statin use and cancer incidence [11–13].
To understand and evaluate the strength of the evidence of the effect of statins on reducing
cancer incidence, we carried out an umbrella review and comprehensively re-analyzed the data of
meta-analyses of randomized controlled trials (RCTs) and observational studies.
2. Materials and Methods
We performed an umbrella review of meta-analyses and systematic reviews reporting on the
associations between statin use and the incidence of cancer. This umbrella review was conducted
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [14]. The PRISMA checklist is shown in the Supplementary Materials.
2.1. Literature Search
We searched the PubMed database and limited the articles to those written in English, regardless
of the publication date. The final search was performed in August 2018. The keywords we used were
the following: ‘(hydroxymethyl glutaryl-coa reductase inhibitor OR statin) AND (cancer OR neoplasm
OR tumor) AND (meta-analysis OR systematic review)’. Meta analyses of either RCTs or observational
studies were included in our search strategy. We reviewed the retrieved articles by examining the titles,
the abstracts, and the full texts, then decided which article to include or exclude. We further searched
the EMBASE database for potentially eligible meta-analyses, but no additional meta-analysis was
included because the identified meta-analyses were lacking data necessary for performing re-analysis
or overlapped with the PubMed search. The detailed search strategy is presented in Figure 1.
2.2. Eligibility Criteria and Data Extraction
We included meta-analyses and systematic reviews of both RCTs and observational studies
reporting on the relationship between statin use and cancer incidence. Observational studies included
both cohort and case-control studies. We excluded review articles without meta-analysis, in vitro
studies, and genetic studies. We also excluded meta-analyses lacking data necessary for performing
re-analysis. If an article presented more than one meta-analysis, all meta-analyses were included and
assessed separately by study design or cancer type.
Two investigators (G.H.J. and J.I.S) independently extracted the data, and discrepancies were
resolved through consensus. We obtained the data from eligible meta-analyses and extracted and
summarized the information on first author, year of publication, the type of cancer, the study design, the
number of included studies, the number of cancer cases and total participants, and the random effects
with a 95% confidence interval (CI). From the eligible studies, we also extracted the raw data of each
individual study for further meta-analysis by combining all data by cancer and study design. If a single
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study consisted of both RCTs and observational studies, we separated the studies according to the
study types (RCTs, observational studies, case-control, and cohort) and reported the results separately.
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2.3. Statistical Analysis
We firstly re-analyzed each meta-analysis and reported the relationship between statin use and
cancer incidence. In addition, if there were overlapping meta-analyses on the same topic, we combined
all the individual studies from eligible meta-analyses according to the type of cancer and study design
and performed a re-meta-analysis after eliminating overlapping individual studies and including
missing individual studies. We presented the summary effect size, 95% CI, and p-value with both
random- and fixed-effects. All re-analyses in this study were performed using the Comprehensive
Meta-Analysis software ver.3.3.070 (Borestein, NH, USA).
2.4. Estimation of Summary Effects and Estimation of Prediction Interval
For each meta-analysis, we re-analyzed the individual studies and estimated the summary effects
and 95% CI using both random- and fixed-effects methods [15]. We also calculated and presented the
95% prediction interval (PI), which address the dispersion of effects (in 95% of cases the true effect in a
new study will fall within the PI) and further account for between-study heterogeneity [16], whereas
CI reflects the accuracy of the mean.
2.5. Evaluation of Bet een-Study Heterogeneity and Small Study Effects
We assessed heterogeneity across the studies using the I2 metric of inconsistency and the p value of
the X2-based Cochrane Q test. I2 values of <50%, 50%–75%, and >75% are usually judged to represent
low or moderate, large and very large heterogeneity, respectively [17].
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Publication bias was evaluated by using Egger’s regression test [18]. Small study effects were
used for detecting publication and reporting bias [19,20]. When the Egger’s test was significant
(p-value < 0.10) in random-effects meta-analyses, we decided that the study has small-study effects.
2.6. Determination of the Level of Evidence
We determined the level of evidence of each meta-analysis and re-analyzed the pooled
meta-analysis to classify the strength of the evidence of the association between statin use and
cancer incidence. The criteria were set according to the statistical significance by random and
fixed-effects p-values, 95% PI, a small-study effects, a between-study heterogeneity, and concordance
between the effect estimate of the largest study and summary estimate of the meta-analysis [21].
The criteria were as follows:
Convincing evidence: There was a statistical significance for the random-effect and fixed-effect
p-values at p < 0.001. No small study effects or large between-study heterogeneity were found, and
95% PI rejected the null hypothesis. There was a concordance between the effect estimate of the largest
study and the summary effect of the random-effects meta-analysis.
Suggestive evidence: There was statistical significance of random effects at p < 0.05, but a 95% PI
included the null hypothesis. No small study effects or large between-study heterogeneity were found.
Weak evidence: There was a statistical significance of random effects at p < 0.05. Small study
effects or large between-study heterogeneity were found.
Non-significant association: There was no statistical significance by random effect meta-analysis
(p > 0.05)
However, if large heterogeneity was found, we rechecked the results to determine whether it
might be due to differences in the direction of the effect or if it could be due to differences in the size of
the association. In the latter case, we re-determined the level of evidence again.
3. Results
3.1. Characteristics of Studies Included in the Final Analyses
A total of 335 meta-analyses was retrieved from our PubMed database search, and 43 eligible
meta-analyses were selected for re-analysis. At first, 171 articles, including 136 duplicate articles,
were excluded by title screening. Another 75 articles were excluded after assessing the abstract, and
46 articles were finally excluded after full text screening. The detailed flow diagram is presented in
Figure 1.
Forty-three meta-analyses eligible for our umbrella review investigated the associations between
statin use and the incidence of 18 types of cancer [22–64]. Information on 43 individual meta-analysis
is presented in Supplementary Table S1.
3.2. Assessing the Effect of Statin on Cancer Incidence with Conventional Interpretation of Meta-Analyses
Criteria (Random Effects p-Value < 0.05)
First, we summarized and re-analyzed the results of the previously reported meta-analysis for
each stain-cancer incidence association, but there were sometimes discordant results among the
meta-analyses of same statin-cancer association. Therefore, we pooled all the individual RCTs and
observational studies extracted from eligible studies without missing or overlapping any studies and
performed re-meta-analysis in 18 types of cancer to reach a final conclusion of association between
statin use and the incidence of one cancer type. Among these, 10 associations (esophageal cancer,
hematological cancer, leukemia, liver cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer,
lymphoma, and prostate cancer) were statistically significant under the conventional interpretation
of meta-analysis criteria (p < 0.05), while eight associations (bladder cancer, endometrial cancer,
gynecological cancer, kidney cancer, melanoma, myeloma, pancreatic cancer, and non-melanoma skin
cancer) were not significant (Table 1).
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Table 1. Summary of meta-analyses by combining all the data on associations of the use of statin and the incidence of cancers.
Cancer Type No ofStudies
No of
Total
Participants
Random
Effects
(RR, 95%CI)
P
(Random)
Fixed Effects
(RR, 95%CI)
P
(Fixed)
Largest
Effect§
(RR, 95%CI)
D/N/I Egger I2 (P) †
95% PI
(Random
Effects)
95% PI
(Fixed
Effects)
Small
Study
Effects
Concordant
Direction Evidence
Bladder cancer 13 1,266,218 1.07(0.95–1.21) 0.282
1.12
(1.07–1.19) <0.001
1.08
(0.99–1.19) 0/11/2 0.851
62.6
(0.001) 0.76–1.51 0.81–1.56 No Yes Non-significant
Breast cancer 62 3,884,629 0.91(0.85–0.97) 0.004
1.00
(0.97–1.02) 0.724
1.04
(0.98–1.11) 12/44/3 0.023
79.6
(<0.001) 0.63–1.32 0.69–1.44 Yes No Weak
Colorectal
cancer 59 13,855,147
0.92
(0.88–0.95) <0.001
0.94
(0.93–0.96) <0.001
0.88
(0.81–0.95) 15/33/3 0.106
71.5
(<0.001) 0.76–1.11 0.78–1.14 No Yes Weak
Endometrial
cancer 15 878,885
0.94
(0.82–1.07) 0.349
1.02
(0.97–1.08) 0.423
1.05
(0.95–1.15) 4/11/0 0.043
54.9
(<0.001) 0.66–1.34 0.73–1.43 Yes Yes Non-significant
Esophageal
cancer 27 3,158,414
0.70
(0.63–0.78) <0.001
0.85
(0.71–0.89) <0.001
0.68
(0.52–0.88) 15/12/0 0.115
60.7
(<0.001) 0.46–1.05 0.50–1.11 No Yes Suggestive *
Gastric cancer 16 5,396,224 0.74(0.60–0.90) 0.004
0.84
(0.79–0.88) <0.001
0.97
(0.74–1.26) 5/11/0 0.325
90.8
(<0.001) 0.33–1.62 0.39–1.78 No No Weak
Gynecological
cancer 23 928,721
0.89
(0.78–1.02) 0.087
1.00
(0.93–1.06) 0.899
1.05
(0.95–1.15) 4/19/0 0.003
43.7
(0.014) 0.62–1.29 0.70–1.41 Yes Yes Non-significant
Hematological
cancer 34 NA
0.89
(0.82–0.96) 0.005
0.86
(0.81–0.90) <0.001 NA ** 7/26/1 0.161
46.7
(0.002) 0.60–1.20 0.64–1.15 No - Suggestive
Kidney cancer 11 4,052,120 0.91(0.70–1.17) 0.457
0.94
(0.88–1.00) 0.034
1.08
(0.99–1.18) 2/9/0 0.722
88.7
(<0.001) 0.39–2.09 0.43–2.05 No Yes Non-significant
Leukemia 9 1174 0.85(0.74–0.98) 0.031
0.83
(0.74–0.92) 0.001
0.74
(0.62–0.87) 2/7/0 0.120
25.0
(0.220) 0.63–1.16 0.62–1.10 No Yes Suggestive
Liver cancer 27 2,622,626 0.58(0.52–0.66) <0.001
0.65
(0.62–0.68) <0.001
0.52
(0.41–0.66) 22/5/0 0.117
83.8
(<0.001) 0.33–1.03 0.38–1.13 No Yes Suggestive *
Lung cancer 33 8,833,965 0.89(0.80–0.99) 0.036
0.82
(0.80–0.84) <0.001
1.03
(0.94–1.21) 5/28/0 0.265
94.9
(<0.001) 0.51–1.57 0.47–1.42 No No Weak
Lymphoma 16 8863 0.85(0.73–0.99) 0.042
0.86
(0.80–0.92) <0.001
0.96
(0.83–1.11) 6/9/1 0.850
69.1
(<0.001) 0.52–1.40 0.54–1.39 No No Weak
Melanoma 24 434,680 0.94(0.86–1.03) 0.204
0.94
(0.88–1.00) 0.063
0.94
(0.88–1.00) 3/21/0 0.836
26.0
(0.121) 0.74–1.19 0.60–1.46 No No Non-significant
Myeloma 5 609 0.89(0.53–1.51) 0.674
0.89
(0.73–1.09) 0.251
0.83
(0.61–1.12) 2/2/1 0.983
81.0
(<0.001) 0.14–5.73 0.17–4.78 No Yes Non-significant
Pancreatic
cancer 20 2,832,052
0.89
(0.75–1.06) 0.207
0.91
(0.86–0.97) 0.003
1.10
(0.81–1.49) 1/18/1 0.927
79.0
(<0.001) 0.46–1.71 0.49–1.71 No Yes Non-significant
Prostate cancer 44 NA 0.94(0.90–0.99) 0.017
1.02
(1.00–1.04) 0.056 NA ** 18/42/4 0.002
74.5
(<0.001) 0.71–1.24 0.78–1.33 Yes - Weak
Non-melanoma
skin cancer 17 1,240,281
1.07
(1.00–1.16) 0.063
1.09
(1.06–1.13) <0.001
1.09
(1.06–1.13) 1/11/5 0.768
58.5
(0.001) 0.88–1.31 0.90–1.32 No No Non-significant
D/N/I: Decreasing risk/No difference/Increasing risk; RR: Relative risk; CI: Confidence interval; PI: Prediction interval. § Relative risk (95% Confidence interval) of the largest study in each
meta-analysis. † I2 metric of inconsistency (95% confidence interval of I2) and p-value of the Cochran Q test for evaluation of heterogeneity. * Suggestive level of evidence due to the greater
number of studies that decrease risk in which a high heterogeneity is due to differences in the effect size of the association. ** Largest effect of study of hematologic and prostate cancer were
not assessible due to lack of number of participants data in individual studies.
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When associations of the meta-analysis summary effect sizes were analyzed with an inverse of
the variance, meta-analyses with small variances showed a trend of summary effects towards 1.00 in
cancer incidence, as shown in Figure 2.
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 6 of 17 
 
3.2. Assessing the Effect of Statin on Cancer Incidence with Conventional Interpretation of Meta-Analyses 
Criteria (Random Effects p-Value < 0.05) 
First, we summarized and re-analyzed the results of the previously reported meta-analysis for 
each stain-cancer incidence association, but there were sometimes discordant results among the meta-
analyses of same statin-cancer association. Therefore, we pooled all the individual RCTs and 
observational studies extracted from eligible studies without missing or overlapping any studies and 
performed re-meta-analysis in 18 types of cancer to reach a final conclusion of association between 
statin use and the incidence of one cancer type. Among these, 10 associations (esophageal cancer, 
hematological cancer, leukemia, liver cancer, breast cancer, colorectal cancer, gastric cancer, lung 
cancer, lymphoma, and prostate cancer) were statistically significant under the conventional 
interpretation of meta-analysis criteria (p < 0.05), while eight associations (bladder cancer, 
endometrial cancer, gynecological cancer, kidney cancer, melanoma, myeloma, pancreatic cancer, 
and non-melanoma skin cancer) were not significant (Table 1). 
When associations of the meta-analysis summary effect sizes were analyzed with an inverse of 
the variance, meta-analyses with small variances showed a trend of summary effects towards 1.00 in 
cancer incidence, as shown in Figure 2. 
 
 
Figure 2. Association of meta-analysis summary effect sizes with the inverse of the variance in cancer 
incidence. 
3.3. Assessing the Statin Effect on Cancer Incidence with Criteria by Previous Umbrella Review 
We determined the level of evidence by not only using random effect p-values but also by using 
between-study heterogeneity, small study effects, and 95% PI according to the methods previously 
published [21]. Under the suggested criteria, we found that none of the associations showed 
convincing evidence, four associations (esophageal cancer, hematological cancer, leukemia and liver 
cancer) were found to show suggestive evidence. Six associations (breast cancer, colorectal cancer, 
gastric cancer, lung cancer, lymphoma, and prostate cancer) showed weak evidence. Details of the 
graded associations are presented in Table 1. 
3.4. Re-Analysis of Meta-Analyses Separated by Study Design 
In addition to the above process, we performed subgroup analyses of eligible meta-analyses by 
study designs (RCTs and observational studies) and carried out a re-meta-analysis of the pooled raw 
data in association with statin use and cancer incidence (Table 2). All overlapping individual studies 
were omitted while pooling the raw data. Details of the individual overlapping meta-analyses with 
different study designs on associations with statin and cancer incidence are summarized in Table 3 
Figure 2. Association of meta-analysis summary effect sizes with the inverse of the variance in
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3.3. Assessing the Statin Effect on Cancer Incidence with Criteria by Previous Umbrella Review
We determined the level of evidence by not only using random effect p-values but also by using
between-study h terogeneity, small study effects, and 95% PI according to the methods previously
published [21]. Under the suggested criteria, w found that none of the associations showed convincing
evidence, four associations (esophag al cancer, hematological c ncer, l ukemia and liver cancer) re
f und to show suggestive evidence. Six associations (breast cancer, colorectal cancer, gastric canc r,
lu g canc r, lymphoma, and prostate cancer) showed weak evidence. Det ils of the graded associations
are prese ted in Table 1.
3.4. Re-Analysis of Meta-Analyses Separated by Study Design
In addition to the above process, we performed subgroup analyses of eligible meta-analyses by
study designs (RCTs and observational studies) an carried out a re-meta-analysis of the pooled raw
data in association with statin use a d cancer incidence (Table 2). All overlapping individual studies
were omitted while pooling the raw data. Details of the individual overlap ing meta-analyses with
diff rent s udy designs o associations with s tin and ca cer ncidenc are sum arized in Table 3
Of the 18 types of cancer, three cancer types (leukemia, lymphoma, and myeloma) did not have
meta-analyses using RCTs. Among the other 15 cancer types, there was no statistically significant
statin–cancer incidence association in meta-analyses of RCTs (Figure 3). For the 18 observational studies,
four cancers (esophageal cancer, hematological cancer, leukemia, and liver cancer) showed suggestive
evidence, seven cancers (breast cancer, colorectal cancer, gastric cancer, lung cancer, lymphoma, prostate
cancer and non-melanoma skin cancer) showed weak evidence, and seven cancers (bladder cancer,
endometrial cancer, gynecological cancer, kidney cancer, melanoma, myeloma and pancreatic cancer)
were not statistically significant. Therefore, the most significant results of statin-cancer associations
were determined by the results of the observational studies.
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Table 2. Re-analysis of the meta-analyses by study design.
Cancer Type Overall Randomized Controlled Studies Observational Studies *
No. of
Studies
Random
Effects
(RR, 95%CI)
p-Value Evidence No. ofStudies
Random
Effects
(RR, 95%CI)
p-Value Evidence No. ofStudies
Random
Effects
(RR, 95%CI)
p-Value Evidence
Bladder cancer 13 1.07 (0.95–1.21) 0.282 Non-significant 3 0.84 (0.64–1.09) 0.180 Non-significant 10 1.11 (0.97–1.26) 0.118 Non-significant
Breast cancer 62 0.91 (0.85–0.97) 0.004 Weak 12 1.00 (0.80–1.25) 0.661 Non-significant 50 0.90 (0.84–0.96) 0.003 Weak
Colorectal
cancer 59 0.92 (0.88–0.95) <0.001 Weak 13 0.92 (0.81–1.05) 0.214 Non-significant 46 0.92 (0.88–0.95) <0.001 Weak
Endometrial
cancer 15 0.94 (0.83–1.07) 0.349 Non-significant 2 0.72 (0.19–2.67) 0.621 Non-significant 13 0.94 (0.82–1.07) 0.361 Non-significant
Esophageal
cancer 27 0.70 (0.63–0.78) <0.001 Suggestive 1 0.98 (0.69–1.40) NR Non-significant 26 0.69 (0.62–0.76) <0.001 Suggestive
Gastric cancer 16 0.74 (0.60–0.90) 0.004 Weak 3 0.84 (0.61–1.14) 0.259 Non-significant 13 0.71 (0.56–0.90) 0.004 Weak
Gynecological
cancer 23 0.89 (0.78–1.02) 0.087 Non-significant 6 1.03 (0.65–1.63) 0.902 Non-significant 17 0.88 (0.76–1.01) 0.069 Non-significant
Hematological
cancer 34 0.89 (0.82–0.96) 0.005 Suggestive 8 0.96 (0.78–1.17) 0.667 Non-significant 26 0.88 (0.81–0.97) 0.006 Suggestive
Kidney cancer 11 0.91 (0.70–1.17) 0.457 Non-significant 2 1.01 (0.57–1.78) 0.985 Non-significant 9 0.90 (0.69–1.18) 0.455 Non-significant
Leukemia 9 0.85 (0.74–0.98) 0.031 Suggestive - - - - 9 0.85 (0.74–0.98) 0.031 Suggestive
Liver cancer 27 0.58 (0.52–0.66) <0.001 Suggestive 3 0.96 (0.62–1.49) 0.867 Non-significant 24 0.57 (0.50–0.65) <0.001 Suggestive
Lung cancer 33 0.89 (0.80–0.99) 0.036 Weak 9 0.95 (0.85–1.05) 0.324 Non-significant 24 0.87 (0.77–0.99) 0.034 Weak
Lymphoma 16 0.85 (0.73–0.99) 0.042 Weak - - - - 16 0.85 (0.73–0.99) 0.042 Weak
Melanoma 24 0.94 (0.86–1.03) 0.204 Non-significant 13 1.06 (0.90–1.25) 0.474 Non-significant 11 0.92 (0.84–1.02) 0.105 Non-significant
Myeloma 5 0.89 (0.53–1.51) 0.674 Non-significant - - - - 5 0.89 (0.53–1.51) 0.674 Non-significant
Pancreatic
cancer 20 0.89 (0.75–1.06) 0.207 Non-significant 3 0.99 (0.44–2.21) 0.982 Non-significant 17 0.89 (0.74–1.07) 0.202 Non-significant
Prostate cancer 64 0.94 (0.90–0.99) 0.017 Weak 7 1.06 (0.93–1.20) 0.386 Non-significant 57 0.93 (0.88–0.98) 0.005 Weak
Non-melanoma
skin cancer 17 1.07 (1.00–1.16) 0.063 Non-significant 8 1.07 (0.86–1.33) 0.519 Non-significant 9 1.08 (1.00–1.18) 0.048 Weak
RR: Relative risk. * Observational studies include both cohort studies and case-control studies.
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Table 3. Summary of individual overlapping meta-analyses with different study designs on associations with statin and cancer incidence.
Cancer Type Overall Randomized Controlled Trials Observational Studies
Number of
Meta-Analyses D/N/I C/S/W
Number of
Meta-Analyses D/N/I C/S/W
Number of
Meta-Analyses D/N/I C/S/W
Bladder cancer 1 0/1/0 0/0/0 1 0/1/0 0/0/0 1 0/1/0 0/0/0
Breast cancer 2 0/2/0 0/0/0 1 0/1/0 0/0/0 3 1/2/0 0/1/0
Colorectal cancer 4 4/0/0 1/0/3 4 0/4/0 0/0/0 5 5/0/0 1/0/4
Endometrial cancer 1 0/1/0 0/0/0 1 0/1/0 0/0/0 1 0/1/0 0/0/0
Esophageal cancer 2 2/0/0 1/0/1 0 0/0/0 0/0/0 6 6/0/0 2/4/0
Gastric cancer 2 2/0/0 0/0/2 1 0/1/0 0/0/0 2 2/0/0 0/0/2
Gynecological cancer 1 0/1/0 0/0/0 1 0/1/0 0/0/0 1 0/1/0 0/0/0
Hematological cancer 2 1/1/0 0/0/1 2 0/2/0 0/0/0 2 1/1/0 0/0/1
Kidney cancer 1 0/0/1 0/0/0 1 0/1/0 0/0/0 1 0/1/0 0/0/0
Leukemia 0 0/0/0 0/0/0 0 0/0/0 0/0/0 1 1/0/0 0/1/0
Liver cancer 3 3/0/0 1/1/1 0 0/0/0 0/0/0 1 1/0/0 0/1/0
Lung cancer 2 0/2/0 0/0/0 3 0/3/0 0/0/0 3 0/3/0 0/0/0
Lymphoma 0 0/0/0 0/0/0 0 0/0/0 0/0/0 2 1/1/0 0/0/1
Melanoma 1 0/1/0 0/0/0 3 0/3/0 0/0/0 0 0/0/0 0/0/0
Myeloma 0 0/0/0 0/0/0 0 0/0/0 0/0/0 1 0/1/0 0/0/0
Pancreatic cancer 2 0/2/0 0/0/0 2 0/2/0 0/0/0 2 0/2/0 0/0/0
Prostate cancer 1 0/1/0 0/0/0 1 0/1/0 0/0/0 6 1/5/0 0/0/1
Non-melanoma skin cancer 2 0/1/1 0/0/1 1 0/1/0 0/0/0 1 0/0/1 0/0/1
D/N/I: Decreasing risk/No difference/Increasing risk; C/S/W: Convincing/Suggestive/Weak.
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4. Discussion
The purpose of this umbrella review of previous meta-analyses and re-analysis of meta-analyses,
including all the individual studies, was to highlight the potential effects of statin use on cancer
incidence. We re-analyzed the data from 43 meta-analyses to evaluate the associations between use of
statins and cancer incidence. By only using a random-effects p-value, 10 of 18 associations of cancer
incidence showed a statistically significant preventive effect of statin.
Although there was a weak or non-significant preventive effect of statin use on most cancer types,
there was a suggestive level of evidence regarding the preventive effects of statin use on four cancer
types (esophageal cancer, hematological cancer, leukemia, and liver cancer). Re-analysis of association
between statin use and leukemia incidence was performed with one eligible meta-analysis [31]
consisting of nine individual studies, which might be relatively a small number of individual studies
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for re-analysis. However, associations of the other three cancer types had an adequate number of
individual studies (27 for esophageal cancer, 34 for hematological cancer, and 27 for liver cancer).
A large number of the included studies for meta-analyses are considered to be valid [65], and, therefore,
the outcomes for the 3 cancer types mentioned above might be plausible. Six types of cancer had weak
evidence due to substantial publication bias and significant heterogeneity established by the I2 value.
Although most of the re-analyses showed weak or non-significant evidence, the conventional
interpretation of current meta-analysis is that there was preventive effect of statin use on cancer
incidence in some cancer types, based on a random effects p-value, an effect size with 95% CI [66].
According to these criteria, 10 of 18 meta-analyses on cancer incidence outcomes demonstrated that
statins have a preventive effect on cancer risk.
In addition, while most of the statistically significant individual meta-analyses showed that statins
have a preventive effect on cancer, one meta-analysis of observational studies on association with statin
and non-melanoma skin cancer suggested that there was a positive relationship between statin and
non-melanoma skin cancer [24]. Yang et al. suggested that meta-analyses of observational studies
might show more noteworthy result due to the characteristic of observational studies, since it may have
advantage of examining rare occurrences of diseases such as cancer. However, the level of evidence
in this study was weak, and it included only one meta-analysis. Therefore, we must scrutinize the
validity of the results. Further meta-analyses with additional studies will be needed.
Our study evaluates the strength of evidence using multiple values presented or calculated in
each meta-analysis. The strength of evidence reinforces the results from the meta-analyses and helps
choose the best evidence. Various methods for assessing the evidence level are presented, yet there
is no definite grading method for an umbrella review [67,68]. Recent umbrella reviews include the
p-value of the meta-analysis, between-study heterogeneity, small study effect, and 95% PI for the
grading the level of evidence, which is more related to quantitative values [20,21,69].
In addition, substantial heterogeneity is an issue in systematic review and meta-analysis. It is
essential to explain and manage the heterogeneity to underline the validity of the respective findings [70].
Umbrella reviews that re-analyze meta-analyses include large number of individual studies, and,
therefore, controlling their heterogeneity can be troublesome. Previous umbrella reviews determined a
large heterogeneity of I2 > 50–75%% as weak evidence [71,72]. However, this application should be
applied cautiously, because heterogeneity can increase if the number of individual studies increases.
In addition, if the heterogeneity is large, it can be due to differences in the direction of the effect, or it
can be due to differences in the size of the association. In the latter case, therefore, we thought the level
of evidence should be re-determined and upgraded the level of evidence from weak to suggestive.
In the eligible meta-analyses, overlapping meta-analyses on the same topic were frequently
reported (Table 3). Overlapping meta-analyses may give an ambiguous result and should be
acknowledged [73]. There are several ways to overcome this problem, and we carried out re-analysis by
merging all the extracted individual studies with coherent data. Integration of data from meta-analyses
might have more strengths than assembling existing reviews [74]. In our study, the incidence of
lymphoma associated with statin use showed a statistically significant outcome with a weak level of
evidence, but two other eligible individual meta-analyses of the same association were not significant
(Supplementary Table S1). Also, re-analysis of the association of incidence of prostate cancer with
statin use was graded as weak evidence, but recent meta-analysis performed by Raval et al. [29] was
not significant. Raval et al. only included 27 individual studies, but our study included a total of
64 individual studies, which highlights that there may have been missing eligible studies even in the
recent meta-analysis. The comparison of the results of our study and the largest meta-analysis are
presented in Table 4.
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Table 4. Comparison of the results with number of included individual studies of our study and the largest meta-analysis.
Type of Cancer
Randomized Controlled Trials Observational Studies
Our Study Largest Meta-Analysis * Our Study Largest Meta-Analysis *
No. of
Study
Random
Effects (RR
95% CI)
No. of
Study
Random
Effects (RR
95% CI)
No. of
Study
Random
Effects (RR
95% CI)
No. of
Study
Random
Effects (RR
95% CI)
Bladder cancer 3 0.84 (0.64–1.09) 3 0.83 (0.64–1.09) 10 1.11 (0.97–1.26) 10 1.11 (0.97–1.26)
Breast cancer 12 1.00 (0.80–1.25) 7 1.19 (0.81–1.73) 50 0.90 (0.84–0.96) 21 0.99 (0.94–1.04)
Colorectal cancer 13 0.92 (0.81–1.05) 11 0.96 (0.85–1.08) 46 0.92 (0.88–0.95) 32 0.92 (0.87–0.96)
Endometrial cancer 2 0.72 (0.19–2.67) 2 0.72 (0.19–2.67) 13 0.94 (0.82–1.07) 13 0.94 (0.82–1.07)
Esophageal cancer 1 0.98 (0.69–1.40) - - 26 0.69 (0.62–0.76) 10 0.59 (0.50–0.68)
Gastric cancer 3 0.84 (0.61–1.14) 3 0.84 (0.61–1.14) 13 0.71 (0.56–0.90) 9 0.70 (0.53–0.93)
Gynecological cancer 6 1.03 (0.65–1.63) 6 1.03 (0.65–1.63) 17 0.88 (0.76–1.01) 17 0.88 (0.76–1.01)
Hematological cancer 8 0.96 (0.78–1.17) 6 0.92 (0.78–1.09) 26 0.88 (0.81–0.97) 22 0.88 (0.80–0.98)
Kidney cancer 2 1.01 (0.57–1.78) 2 1.01 (0.57–1.78) 9 0.90 (0.69–1.18) 9 0.90 (0.69–1.18)
Leukemia - - - - 9 0.85 (0.74–0.98) 9 0.85 (0.74–0.98)
Liver cancer 3 0.96 (0.62–1.49) - - 24 0.57 (0.50–0.65) 6 0.58 (0.46–0.74)
Lung cancer 9 0.95 (0.85–1.05) 7 0.95 (0.84–1.09) 24 0.87 (0.77–0.99) 15 0.88 (0.75–1.03)
Lymphoma - - - - 16 0.85 (0.73–0.99) 13 0.83 (0.69–0.99)
Melanoma 13 1.06 (0.90–1.25) 9 0.92 (0.62–1.36) 11 0.92 (0.84–1.02) - -
Myeloma - - - - 5 0.89 (0.53–1.51) 5 0.89 (0.53–1.51)
Pancreatic cancer 3 0.99 (0.44–2.21) 3 0.99 (0.44–2.21) 17 0.89 (0.74–1.07) 15 0.88 (0.73–1.07)
Prostate cancer 7 1.06 (0.93–1.20) 6 1.06 (0.93–1.20) 57 0.93 (0.88–0.98) 27 0.90 (0.80–1.01)
Non-melanoma skin cancer 8 1.07 (0.86–1.33) 7 1.09 (0.85–1.39) 9 1.08 (1.00–1.18) 5 1.11 (1.02–1.22)
RR: Relative risk; CI: Confidence interval. * Meta-analysis including largest number of individual studies.
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Results of the meta-analysis can be influenced by study design. Aromataris et al. reported that
the types of studies should be matched in systematic reviews, and meta-analyses to be considered
for its primary objective [75]. In our study, no meta-analysis that included only RCTs showed a
significant preventive effect of statin use on cancer incidence, but re-analyses of observational studies
showed statistically significant findings in 11 of the 18 statin–cancer associations. Among these
11 associations, the results of the overall studies (RCTs and observational studies) were determined by
those of observational studies in 10 cancers, except non-melanoma skin cancer, for which the results
were determined by RCTs. The heterogeneity between overall study design and observational studies
may be due to the relatively large number of observational studies included. In addition, observational
studies tend to have more biases than RCTs [76], and some reports suggest that the outcomes of
observed associations could be false positives or inflated if a large between-study heterogeneity is
present [77,78]. However, meta-analysis of RCTs should be interpreted carefully because cancer events
are not the primary endpoints of clinical trials. Besides, duration of treatment in clinical trials was
relatively shorter than that in observational studies, so there may be an uncertainty of the association.
Our study has several limitations. First, we only assessed individual studies from systematic
reviews and meta-analyses eligible for re-analysis, and, therefore, some very recent individual studies
might have been missed. However, considering that even a very recent updated meta-analysis for one
cancer missed many individual studies, even though thorough search strategy was performed using
many search sites such as PubMed, Embase, Scopus, Cochrane database, etc., we think that one should
also check the individual studies from previous meta-analyses when updating the meta-analysis.
Second, individual studies can have biases, but assessing the quality of individual studies was beyond
the scope of our review. Third, exploring the association between dose and types of statins and cancer
incidence was also beyond the scope. Likewise, due to a lack of applicable data, we could not stratify
the effect of statins by participant age or duration of treatment, which may be the parameter needed to
evaluate the true association. Fourth, there were statistical limitations. A 95% PI and Egger p-value
could not be assessed if there were only two or fewer individual studies. There were also some missing
data in the largest study effect when there was no number of population data in individual studies.
Finally, 95% PI, between-study heterogeneity, and publication bias may not be definitive criteria for
assessing the strength of the evidence.
Nevertheless, in summary, we extensively re-analyzed meta-analyses on the associations between
statin use and cancer incidence. In 10 of 18 studies there were significant relationships between
statin use and cancer incidence. Although many meta-analyses of RCTs and observational studies
reported significant associations between statin use and cancer incidence, only a small portion of these
associations were without biases. Also, there was an individual meta-analysis reporting increased
risk of cancer associated with statins use, which should be carefully interpreted by researchers and
clinicians. Future studies should include more precise individual data, assessment of potential bias,
and updated meta-analyses with more qualified RCTs and observational studies. We suggest that
clinicians carefully consider the effects of statins on incidence of different types of cancer on the basis
of the findings of our study.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/6/819/s1,
Table S1. Reanalysis of each meta-analysis on associations of the use of statin and the incidence of cancers, Table S2.
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